TY  - JOUR 
AU  - González, Mónica Del Rey
AU  - Chakraborty, Sohini
AU  - Hernández Sánchez, Jesús María
AU  - Díez Campelo, María
AU  - Park, Christopher Y
AU  - Hernández Rivas, Jesús María
PY  - 2024
SN  - 2234-943X
UR  - http://hdl.handle.net/10366/172059
AB  - [EN]Treatment with the hypomethylating agent 5-azacytidine (AZA) increases survival in high-risk (HR) myelodysplastic syndrome (MDS) patients, but predicting patient response and overall survival remains challenging. To address these issues, we...
LA  - eng
KW  - agent 5-azacytidine
KW  - síndromes mielodisplásicos (SMD)
TI  - Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response
DO  - 10.3389/fonc.2024.1438052
T2  - Frontiers in oncology
VL  - 14
M2  - 1438052
ER  -